Wednesday, 18 June 2014
Cineworld: The O2, London, SE10 0DX, UK
This meeting discusses new developments in therapeutic protein and antibody engineering with specific focus on science and technology of modifying proteins and antibodies (and the conditions of their manufacture) toward specific predefined properties that allow them to act as effective biological drugs. Special emphasis will be placed on structure-function relationships, mechanisms of action, potency and efficacy in disease-relevant models and in clinical trials. There will be plenty of opportunity for discussion and debate addressing the wide range of disciplines applied to the rapid and economical production of these molecules for biological therapies
This event has CPD accreditation
Meeting chair: Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King’s College London School of Medicine, UK
Who Should Attend
All academic and biotechnology/biopharma professionals interested in biological protein and antibody engineering, functional and potency evaluations; also scientists interested in biological therapeutics mechanisms of action and translational implications for therapy.
The Deadline for abstract submissions for oral presentation is April 10th 2014
Abstracts for poster presentation only can be submitted up to two weeks before the event
You can download the instructions for authors at
www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
